NEWSROOM
Press Releases by Agendia
News
Press Releases
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MARCH 31, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patient’s sample and the safety of Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 13, 2020 – Agendia, Read More
Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 January 2020 – Laura Read More
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse IRVINE, CALIF., U.S. and Amsterdam – 3 January 2020 – Agendia Inc., a world leader in precision Read More
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, December 12, 2019 – Agendia, Inc., a world leader in precision oncology for Read More
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer patients IRVINE, CALIF. – 19 November Read More
